CAH · Cardinal Health Inc · Executive Compensation

Track CAH — free

$228.62 +6.12 (+2.75%)

Ex-dividend: $0.5158 · Oct 1, 2026 Return incl. dividend (before tax) +2.98%

S&P 500 member Russell 1000 member Rebalance outlook locked

Market Cap

$52.08B

232.58M

Volume · Oct 1 725.43K Avg daily vol (3M) 1.98M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2026

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Jason M. Hollar	Chief Executive Officer	$1,500,000	—	$16,259,918	—	$4,278,750	$535,681	$22,574,349
Aaron E. Alt	Chief Financial Officer	$896,233	—	$4,318,999	—	$1,606,945	$37,996	$6,860,173
Deborah L. Weitzman	Chief Executive Officer, Pharmaceutical and Specialty Solutions Segment	$770,479	—	$4,064,943	—	$1,254,340	$30,395	$6,120,157
Jessica L. Mayer	Chief Legal and Compliance Officer	$741,233	—	$3,556,822	—	$1,208,210	$27,918	$5,534,183
Stephen M. Mason	Chief Executive Officer, Global Medical Products and Distribution Segment	$761,986	—	$3,404,479	—	$1,112,500	$14,400	$5,293,365

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Jason Hollar	Chief Executive Officer	$1,492,329	—	$13,431,441	—	$3,551,742	$500,683	$18,976,195
Jason M. Hollar	Chief Executive Officer	$1,492,329	—	$13,431,441	—	$3,551,742	$500,683	$18,976,195
Aaron E. Alt	Chief Financial Officer	$871,164	—	$3,977,813	—	$1,303,262	$57,796	$6,210,035
Deborah L. Weitzman	Chief Executive Officer, Pharmaceutical and Specialty Solutions Segment	$741,932	—	$3,771,217	—	$964,511	$30,197	$5,507,857
Jessica L. Mayer	Chief Legal and Compliance Officer	$716,932	—	$3,202,943	—	$975,027	$30,450	$4,925,352
Stephen M. Mason	Chief Executive Officer, Global Medical Products and Distribution Segment	$741,932	—	$3,357,917	—	$593,545	$51,650	$4,745,044

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Jason M. Hollar	Chief Executive Officer	$1,434,153	—	$20,640,912	—	$3,112,112	$464,032	$25,651,209
Jason Hollar	Chief Executive Officer	$1,434,153	$0	$20,640,912	$0	$3,112,112	$463,532	$25,650,709
Stephen M. Mason	Chief Executive Officer, Global Medical Products and Distribution Segment	$721,038	—	$5,973,322	—	$627,303	$16,150	$7,337,813
Aaron E. Alt	Chief Financial Officer	$846,038	—	$4,824,118	—	$1,153,996	$18,749	$6,842,901
Deborah L. Weitzman	Chief Executive Officer, Pharmaceutical and Specialty Solutions Segment	$709,153	—	$3,598,977	—	$758,794	$21,923	$5,088,847
Jessica L. Mayer	Chief Legal and Compliance Officer	$696,038	—	$3,084,840	—	$863,087	$13,800	$4,657,765

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Jason Hollar	Chief Executive Officer	$1,245,534	$0	$14,828,888	$0	$2,383,757	$325,588	$18,783,767
Jason M. Hollar	Chief Executive Officer	$1,245,534	$0	$14,828,888	$0	$2,383,757	$325,588	$18,783,767
Aaron E. Alt	Chief Financial Officer	$375,205	$1,000,000	$3,815,637	$0	$544,798	$265,008	$6,000,648
Victor L. Crawford	Former Chief Executive Officer, Pharmaceutical Segment	$280,673	$0	$3,184,155	$0	$0	$1,304,776	$4,769,604
Stephen M. Mason	Chief Executive Officer, Global Medical Products and Distribution Segment	$695,959	$0	$3,184,155	$0	$521,969	$13,200	$4,415,283
Jessica L. Mayer	Chief Legal and Compliance Officer	$666,918	$0	$2,918,878	$0	$800,302	$13,200	$4,399,298
Deborah L. Weitzman	Chief Executive Officer, Pharmaceutical and Specialty Solutions Segment	$606,139	$0	$2,672,523	$0	$773,979	$17,810	$4,070,451
Michael Kaufmann	Former Chief Executive Officer	$233,014	$0	$0	$0	$0	$3,295,954	$3,528,968
Patricia M. English	Former Interim Chief Financial Officer	$291,465	$0	$811,405	$0	$146,705	$13,174	$1,262,749

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Michael Kaufmann	Former Chief Executive Officer	$1,341,781	$0	$11,051,066	$0	$805,068	$265,642	$13,463,557
Jessica L. Mayer	Chief Legal and Compliance Officer	$616,781	$0	$4,261,614	$0	$244,245	$12,426	$5,135,066
Jason Hollar	Chief Executive Officer	$729,247	$0	$2,762,792	$0	$320,869	$69,791	$3,882,699
Jason M. Hollar	Chief Executive Officer	$729,247	$0	$2,762,792	$0	$320,869	$69,791	$3,882,699
Victor L. Crawford	Former Chief Executive Officer, Pharmaceutical Segment	$741,295	$0	$2,762,792	$0	$296,518	$12,200	$3,812,805
Stephen M. Mason	Chief Executive Officer, Global Medical Products and Distribution Segment	$666,781	$0	$2,762,792	$0	$166,695	$15,403	$3,611,671

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Michael Kaufmann	Former Chief Executive Officer	$1,300,000	$0	$10,197,832	$0	$780,000	$204,546	$12,482,378
Victor L. Crawford	Former Chief Executive Officer, Pharmaceutical Segment	$725,000	$0	$2,804,433	$0	$652,500	$35,894	$4,217,827
Jason Hollar	Chief Executive Officer and Former Chief Financial Officer	$700,000	$0	$2,549,444	$0	$630,000	$71,416	$3,950,860
Jason M. Hollar	Chief Executive Officer and Former Chief Financial Officer	$700,000	$0	$2,549,444	$0	$630,000	$71,416	$3,950,860
Stephen M. Mason	Chief Executive Officer, Medical Segment	$625,000	$0	$2,549,444	$0	$562,500	$17,256	$3,754,200
Jessica L. Mayer	Chief Legal and Compliance Officer	$575,000	$0	$1,886,574	$0	$465,750	$11,810	$2,939,134

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Michael Kaufmann	Chief Executive Officer	$1,286,612	$0	$10,239,990	$0	$2,547,492	$143,033	$14,217,127
Victor L. Crawford	Chief Executive Officer — Pharmaceutical Segment	$721,653	$0	$2,815,992	$0	$909,283	$14,250	$4,461,178
Jason M. Hollar	Chief Financial Officer	$124,317	$1,550,000	$2,067,619	$0	$149,180	$213,137	$4,104,253
Jason Hollar	Chief Financial Officer	$124,317	$1,550,000	$2,067,619	$0	$149,180	$213,137	$4,104,253
Stephen M. Mason	Chief Executive Officer — Medical Segment	$511,749	$0	$2,304,024	$0	$586,348	$21,350	$3,423,471
Jessica L. Mayer	Chief Legal and Compliance Officer The amounts reported represent the aggregate accounting value of PSUs and RSUs granted during each fiscal year. The amounts reported in each fiscal year do not represent amounts paid to or realized by the named executives. See the Grants of Plan-Based Awards for Fiscal 2022 table on page 59 and the accompanying footnotes for information on the accounting value of each award granted in fiscal 2022. The accounting values of the PSUs granted during fiscal 2022 assuming that the highest level of performance conditions will be achieved are: Mr. Kaufmann — 15,563,620; Mr. Hollar — 3,890,880; Mr. Crawford — 3,890,880; Mr. Mason — 3,890,880; and Ms. Mayer — 3,537,225. Mr. Hollar was elected Chief Executive Officer and Mr. Kaufmann departed from the company, each effective September 1, 2022. Mr. Crawford ceased to serve as Chief Executive Officer, Pharmaceutical Segment effective September 19, 2022, and he will depart from the company on November 13, 2022. Under the standard terms of our 2011 LTIP applicable to all retirement-eligible participants, the unvested portions of these awards vest on a prorated basis when the named executive leaves the company, and the remaining portions are forfeited. Vested PSUs pay out based on actual performance. The amount shown in this column for 2022 includes RSUs with an accounting value of 1,750,003 granted to Ms. Mayer in November 2021 to move her total direct compensation closer to the median of the Comparator Group market data for chief legal officer roles.	$547,268	$0	$1,792,014	$0	$559,061	$15,859	$2,914,202
David C. Evans	Former interim Chief Financial Officer	$2,178,361	$0	$0	$0	$0	$26,850	$2,205,211
Jorge M. Gomez	Former Chief Financial Officer The amounts reported represent the aggregate accounting value of PSUs (at target) and RSUs granted during each fiscal year. The amounts reported in each fiscal year do not represent amounts paid to or realized by the named executives. See the Grants of Plan-Based Awards for Fiscal 2020 table on page 42 and the accompanying footnotes for information on the accounting value of each award granted in fiscal 2020. The accounting values of the PSUs granted during fiscal 2020 at target are: Mr. Kaufmann — 6,239,994; Mr. Hollar — 1,067,620; Mr. Crawford — 1,716,012; Mr. Mason — 1,404,006; and Ms. Mayer — 1,092,000. The accounting values of the PSUs granted during fiscal 2020 assuming that the highest level of performance conditions will be achieved are: Mr. Kaufmann — 14,975,994; Mr. Hollar — 2,562,308; Mr. Crawford — 4,118,412; Mr. Mason — 3,369,606; and Ms. Mayer — 2,620,800. Mr. Kaufmann also served as interim Chief Financial Officer from August 9, 2019 until August 31, 2019. Mr. Hollar joined us on April 27, 2020 and became Chief Financial Officer on May 26, 2020. To address compensation forfeited at his former employer, Mr. Hollar received a sign-on bonus of 1,550,000, PSUs with an accounting value of 1,067,620 and RSUs with an accounting value of 1,000,000. He also received a 200,000 lump sum payment for relocation. He must repay the full sign-on bonus and relocation payment if he voluntarily leaves the company during the first year following his start date and 50% of it if he leaves during the second year following his start date. Mr. Mason was not previously a named executive. Mr. Evans served as interim Chief Financial Officer from September 1, 2019 until May 25, 2020. In his interim role, he received monthly cash compensation of 220,000 during his employment and did not participate in our annual or long-term incentive plans or our Severance Plan. Mr. Gomez served as Chief Financial Officer from the beginning of the fiscal year through August 8, 2019, when he left the company.	$65,574	$0	$0	$0	$0	$2,951	$68,525

Fiscal 2019

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Michael Kaufmann	Chief Executive Officer	$1,193,288	$0	$12,110,701	$0	$2,126,439	$140,576	$15,571,004
Victor L. Crawford	Chief Executive Officer — Pharmaceutical Segment	$443,014	$2,500,000	$3,095,770	$0	$502,378	$184,660	$6,725,822
Jorge M. Gomez	Former Chief Financial Officer The amounts reported represent the aggregate accounting value of PSUs (at target) and RSUs granted during each fiscal year. The amounts reported in each fiscal year do not represent amounts paid to or realized by the named executives. See the Grants of Plan-Based Awards for Fiscal 2020 table on page 42 and the accompanying footnotes for information on the accounting value of each award granted in fiscal 2020. The accounting values of the PSUs granted during fiscal 2020 at target are: Mr. Kaufmann — 6,239,994; Mr. Hollar — 1,067,620; Mr. Crawford — 1,716,012; Mr. Mason — 1,404,006; and Ms. Mayer — 1,092,000. The accounting values of the PSUs granted during fiscal 2020 assuming that the highest level of performance conditions will be achieved are: Mr. Kaufmann — 14,975,994; Mr. Hollar — 2,562,308; Mr. Crawford — 4,118,412; Mr. Mason — 3,369,606; and Ms. Mayer — 2,620,800. Mr. Kaufmann also served as interim Chief Financial Officer from August 9, 2019 until August 31, 2019. Mr. Hollar joined us on April 27, 2020 and became Chief Financial Officer on May 26, 2020. To address compensation forfeited at his former employer, Mr. Hollar received a sign-on bonus of 1,550,000, PSUs with an accounting value of 1,067,620 and RSUs with an accounting value of 1,000,000. He also received a 200,000 lump sum payment for relocation. He must repay the full sign-on bonus and relocation payment if he voluntarily leaves the company during the first year following his start date and 50% of it if he leaves during the second year following his start date. Mr. Mason was not previously a named executive. Mr. Evans served as interim Chief Financial Officer from September 1, 2019 until May 25, 2020. In his interim role, he received monthly cash compensation of 220,000 during his employment and did not participate in our annual or long-term incentive plans or our Severance Plan. Mr. Gomez served as Chief Financial Officer from the beginning of the fiscal year through August 8, 2019, when he left the company.	$593,288	$0	$2,530,734	$0	$0	$26,757	$3,150,779
Jessica L. Mayer	Chief Legal and Compliance Officer The amounts reported represent the aggregate accounting value of PSUs (at target) and RSUs granted during each fiscal year. The amounts reported in each fiscal year do not represent amounts paid to or realized by the named executives. See the Grants of Plan-Based Awards for Fiscal 2021 table on page 61 and the accompanying footnotes for information on the accounting value of each award granted in fiscal 2021. The accounting values of the PSUs granted during fiscal 2021 at target are: Mr. Kaufmann — 6,197,813; Mr. Hollar — 1,549,439; Mr. Crawford — 1,704,422; Mr. Mason — 1,549,439; and Ms. Mayer — 1,146,595. The accounting values of the PSUs granted during fiscal 2021 assuming that the highest level of performance conditions will be achieved are: Mr. Kaufmann — 14,502,892; Mr. Hollar — 3,625,709; Mr. Crawford — 3,920,149; Mr. Mason — 3,625,709; and Ms. Mayer — 2,683,059.	$429,856	$0	$2,152,539	$0	$364,933	$19,707	$2,967,035

Fiscal 2018

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Michael Kaufmann	Chief Executive Officer	$955,699	$0	$4,900,007	$948,690	$1,518,780	$100,404	$8,423,580
Jorge M. Gomez	Former Chief Financial Officer The amounts reported represent the aggregate accounting value of PSUs (at target) and RSUs granted during each fiscal year. The amounts reported in each fiscal year do not represent amounts paid to or realized by the named executives. See the Grants of Plan-Based Awards for Fiscal 2020 table on page 42 and the accompanying footnotes for information on the accounting value of each award granted in fiscal 2020. The accounting values of the PSUs granted during fiscal 2020 at target are: Mr. Kaufmann — 6,239,994; Mr. Hollar — 1,067,620; Mr. Crawford — 1,716,012; Mr. Mason — 1,404,006; and Ms. Mayer — 1,092,000. The accounting values of the PSUs granted during fiscal 2020 assuming that the highest level of performance conditions will be achieved are: Mr. Kaufmann — 14,975,994; Mr. Hollar — 2,562,308; Mr. Crawford — 4,118,412; Mr. Mason — 3,369,606; and Ms. Mayer — 2,620,800. Mr. Kaufmann also served as interim Chief Financial Officer from August 9, 2019 until August 31, 2019. Mr. Hollar joined us on April 27, 2020 and became Chief Financial Officer on May 26, 2020. To address compensation forfeited at his former employer, Mr. Hollar received a sign-on bonus of 1,550,000, PSUs with an accounting value of 1,067,620 and RSUs with an accounting value of 1,000,000. He also received a 200,000 lump sum payment for relocation. He must repay the full sign-on bonus and relocation payment if he voluntarily leaves the company during the first year following his start date and 50% of it if he leaves during the second year following his start date. Mr. Mason was not previously a named executive. Mr. Evans served as interim Chief Financial Officer from September 1, 2019 until May 25, 2020. In his interim role, he received monthly cash compensation of 220,000 during his employment and did not participate in our annual or long-term incentive plans or our Severance Plan. Mr. Gomez served as Chief Financial Officer from the beginning of the fiscal year through August 8, 2019, when he left the company.	$478,149	$0	$1,294,742	$163,519	$387,356	$37,527	$2,361,293

Executive changes

Person	Role	Change	Effective	Filed
Anita Zielinski	Senior Vice President Finance	Appointed	2026-09-16	2026-08-05
Anita Zielinski	Chief Accounting Officer	Appointed	2026-11-05	2026-08-05
Patricia A. Hemingway Hall	Board Chair	Appointed	2026-03-17	2026-03-23
Gregory B. Kenny	Board of Directors	Retired	2026-03-20	2026-03-23
Gregory B. Kenny	Board Chair	Retired	2026-03-20	2026-03-23
Sudhakar Ramakrishna	Director	Appointed	2025-03-07	2025-03-10
Robert W. Musslewhite	Director	Appointed	2025-03-07	2025-03-10
Robert W. Azelby	Board of Directors	Appointed	2024-03-01	2024-02-28
Aaron E. Alt	Chief Financial Officer	Appointed	2023-02-10	2022-12-19
Debbie Weitzman	CEO of the Company's Pharmaceutical Segment	Appointed	—	2022-09-08
Victor L. Crawford	Chief Executive Officer, Pharmaceutical Segment	Terminated	2022-09-19	2022-09-08
Michelle Brennan	independent director	Appointed	—	2022-09-06
Sujatha Chandrasekaran	independent director	Appointed	—	2022-09-06
Christine Mundkur	independent director	Appointed	—	2022-09-06
Steven Barg	independent director	Appointed	—	2022-09-06
Christine A. Mundkur	new independent member of the Board	Appointed	2022-09-06	2022-09-06
Michelle M. Brennan	new independent member of the Board	Appointed	2022-09-06	2022-09-06
Sujatha Chandrasekaran	new independent member of the Board	Appointed	2022-09-06	2022-09-06
Steven K. Barg	new independent member of the Board (Investor Designee)	Appointed	2022-09-06	2022-09-06
Patricia M. English	Interim CFO	Appointed	2022-09-01	2022-08-11
Mary C. Scherer	Senior Vice President and Chief Accounting Officer	Appointed	2022-09-01	2022-08-11
Michael C. Kaufmann	member of the Board	Resigned	2022-09-01	2022-08-11
Jason M. Hollar	director	Appointed	2022-08-11	2022-08-11
Jason M. Hollar	Chief Executive Officer ("CEO")	Appointed	2022-09-01	2022-08-11

Key facts CIK 721371 CUSIP 14149Y108 13F (30d) 30 filings 17 filers Visit website Investor relations